GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Novo Integrated Sciences Inc (NAS:NVOS) » Definitions » Altman Z2-Score

Novo Integrated Sciences (Novo Integrated Sciences) Altman Z2-Score : -7.81 (As of May. 22, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Novo Integrated Sciences Altman Z2-Score?

Altman Z2-Score, also known as Z"-Score, is used to predict the likelihood that a non-manufacturing company (excluding property/financial company) will face bankruptcy within a two-year period.

Warning Sign:

Novo Integrated Sciences has a Altman Z2-Score of -7.81, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.

The zones of discrimination were as such:

When Altman Z2-Score <= 1.1, it is in Distress Zones.
When Altman Z2-Score >= 2.6, it is in Safe Zones.
When Altman Z2-Score is between 1.1 and 2.6, it is in Grey Zones.

The historical rank and industry rank for Novo Integrated Sciences's Altman Z2-Score or its related term are showing as below:

NVOS' s Altman Z2-Score Range Over the Past 10 Years
Min: -3494.85   Med: -8.11   Max: 5.46
Current: -7.81

During the past 13 years, Novo Integrated Sciences's highest Altman Z2-Score was 5.46. The lowest was -3494.85. And the median was -8.11.


Novo Integrated Sciences Altman Z2-Score Historical Data

The historical data trend for Novo Integrated Sciences's Altman Z2-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Integrated Sciences Altman Z2-Score Chart

Novo Integrated Sciences Annual Data
Trend Dec14 Dec15 Dec16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23
Altman Z2-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.23 1.25 -8.58 -5.97

Novo Integrated Sciences Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Altman Z2-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.68 -8.15 -5.97 -6.90 -7.81

Competitive Comparison of Novo Integrated Sciences's Altman Z2-Score

For the Medical Care Facilities subindustry, Novo Integrated Sciences's Altman Z2-Score, along with its competitors' market caps and Altman Z2-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Novo Integrated Sciences's Altman Z2-Score Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Altman Z2-Score distribution charts can be found below:

* The bar in red indicates where Novo Integrated Sciences's Altman Z2-Score falls into.



Novo Integrated Sciences Altman Z2-Score Calculation

Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.

Z2-Score, also known as Z"-Score is the Z-Score for non-manufacturing companies excluding property/financial companies.

Novo Integrated Sciences's Altman Z2-Score for today is calculated with this formula:

Z=6.56*X1+3.26*X2+6.72*X3+1.05*X4_2
=6.56*-0.1413+3.26*-2.1305+6.72*-0.2565+1.05*1.6991
=-7.81

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z2-Score when X4_2 value is 0.

Trailing Twelve Months (TTM) ended in Feb. 2024:
Total Assets was $34.95 Mil.
Total Current Assets was $5.02 Mil.
Total Current Liabilities was $9.96 Mil.
Retained Earnings was $-74.46 Mil.
Pre-Tax Income was -2.746 + -4.661 + -3.202 + -1.485 = $-12.09 Mil.
Interest Expense was -1.253 + -1.219 + -0.49 + -0.166 = $-3.13 Mil.
Total Liabilities was $13.06 Mil.

* Note that for stock reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data.

X1=Working Capital/Total Assets
=(Total Current Assets - Total Current Liabilities)/Total Assets
=(5.019 - 9.959)/34.949
=-0.1413

X2=Retained Earnings/Total Assets
=-74.46/34.949
=-2.1305

X3=Earnings Before Interest and Taxes/Total Assets
=(Pre-Tax Income - Interest Expense)/Total Assets
=(-12.094 - -3.128)/34.949
=-0.2565

X4_2=Net Worth/Total Liabilities
=(Total Stockholders Equity - Preferred Stock)/Total Liabilities
=(22.189 - 0)/13.059
=1.6991

The zones of discrimination were as such:

Distress Zones - 1.1 < Grey Zones < 2.6 - Safe Zones

Novo Integrated Sciences has a Altman Z2-Score of -7.81 indicating it is in Distress Zones.


Novo Integrated Sciences  (NAS:NVOS) Altman Z2-Score Explanation

The original Z-Score model was based on publicly traded manufacturing companies while the Z2-Score, also known as Z"-score can be used for any type of company excluding property/financial companies. Both Z-Score and Z2-Score describes the financial health of a company, and its likelihood of financial distress.

X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.

X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.

X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.

X4_2, Net Worth (Total Stockholders Equity - Preferred Stock)/Total Liabilities (NW/TL): it compares a company’s stock net worth with its total liabilities and can be used to assess the extent of its reliance on debt.

Read more about Altman Z2-Score, the original research on Z-Score and the additional research on Z2-Score.


Be Aware

Altman Z2-Score does not apply to financial companies.


Novo Integrated Sciences Altman Z2-Score Related Terms

Thank you for viewing the detailed overview of Novo Integrated Sciences's Altman Z2-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Novo Integrated Sciences (Novo Integrated Sciences) Business Description

Traded in Other Exchanges
N/A
Address
11120 NE 2nd Street, Suite 100, Bellevue, WA, USA, 98004
Novo Integrated Sciences Inc is a medical care company. It provides specialized physiotherapy, chiropractic care, occupational therapy, eldercare, laser therapeutics, massage therapy, acupuncture, neurological functions, kinesiology, and others. It has two reportable segments: healthcare services which generates majority of the revenue, and product sales.
Executives
Sarfaraz Ali director C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Robert Letterio Oliva director 115 BELFIELD RD, TORONTO A6 L0J 1C0
Sterling M. Jimenez officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Michael Ross Pope director 1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043
Alex Flesias director 41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7
Michael Joseph Gaynor director 49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0
Robert Mattacchione director, 10 percent owner, officer: Chief Executive Officer 79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1
Pierre Joseph Dalcourt director, 10 percent owner 35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0
Christopher Mehlin David director, officer: President 10425 SE 22ND ST., BELLEVUE WA 98004
Thomas Edward Bray officer: Principal Financial Officer C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004
Rebecca Aw Mcdonald officer: Chief Accounting Officer 1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724
James Jr Teters director 1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724
Phyllis Rouse officer: secretary 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Jay Hilden officer: President & CEO 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724
Robert Adamo director 1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724